PE20210974A1 - Composicion de cannabinoides y metodo para tratar el ptsd y/o la ansiedad - Google Patents

Composicion de cannabinoides y metodo para tratar el ptsd y/o la ansiedad

Info

Publication number
PE20210974A1
PE20210974A1 PE2020002273A PE2020002273A PE20210974A1 PE 20210974 A1 PE20210974 A1 PE 20210974A1 PE 2020002273 A PE2020002273 A PE 2020002273A PE 2020002273 A PE2020002273 A PE 2020002273A PE 20210974 A1 PE20210974 A1 PE 20210974A1
Authority
PE
Peru
Prior art keywords
anxiety
cannabinoid composition
treat ptsd
ptsd
treat
Prior art date
Application number
PE2020002273A
Other languages
English (en)
Inventor
Harry Karelis
Original Assignee
Zelira Therapeutics Operations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zelira Therapeutics Operations Pty Ltd filed Critical Zelira Therapeutics Operations Pty Ltd
Publication of PE20210974A1 publication Critical patent/PE20210974A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La invencion se relacion con una composicion farmaceutica que comprende delta-9-tetrahidrocannabinol (THC), cannabidiol (CBD) y una fraccion de terpenos obtenida por extraccion de una planta de Cannabis y su uso en el tratamiento de la ansiedad y/o el trastorno de estres postraumatico (PTSD).
PE2020002273A 2018-07-03 2019-07-03 Composicion de cannabinoides y metodo para tratar el ptsd y/o la ansiedad PE20210974A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2018100925A AU2018100925A4 (en) 2018-07-03 2018-07-03 Cannabinoid composition and method for treating PTSD and/or anxiety
PCT/AU2019/050698 WO2020006597A1 (en) 2018-07-03 2019-07-03 Cannabinoid composition and method for treating ptsd and/or anxiety

Publications (1)

Publication Number Publication Date
PE20210974A1 true PE20210974A1 (es) 2021-05-25

Family

ID=63079634

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020002273A PE20210974A1 (es) 2018-07-03 2019-07-03 Composicion de cannabinoides y metodo para tratar el ptsd y/o la ansiedad

Country Status (13)

Country Link
US (1) US20210308092A1 (es)
EP (1) EP3817735A4 (es)
KR (1) KR20210071940A (es)
AU (2) AU2018100925A4 (es)
BR (1) BR112020027060A2 (es)
CA (1) CA3104739A1 (es)
CL (1) CL2020003374A1 (es)
CO (1) CO2021001059A2 (es)
IL (1) IL279799A (es)
MX (1) MX2021000024A (es)
PE (1) PE20210974A1 (es)
SG (1) SG11202013235YA (es)
WO (1) WO2020006597A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220160648A1 (en) * 2019-02-13 2022-05-26 Inspired Health Products, LLC Composition Comprising Hydrolyzed Collagen and Cannabidiol and Use Thereof
CN110433133A (zh) * 2019-08-19 2019-11-12 中国人民解放军军事科学院军事医学研究院 治疗创伤后应激障碍的大麻二酚鼻用制剂
WO2023034568A1 (en) * 2021-09-03 2023-03-09 Yale University Specific therapeutic medical marijuana doses for stress and pain

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2895805A1 (en) * 2012-12-18 2014-06-26 Kotzker Consulting Llc Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
CA2965493C (en) * 2014-10-21 2021-12-07 United Cannabis Corp. Cannabis extracts and methods of preparing and using same
CA2952335A1 (en) * 2015-12-19 2017-06-19 Delta 9 Gardening B.V. Therapeutic delivery formulations and systems comprising cannabinoids and terpenes
CA3017696A1 (en) * 2016-03-16 2017-09-21 Buzzelet Development And Technologies Ltd Terpene-enriched cannabinoid composition
WO2018222923A1 (en) * 2017-05-31 2018-12-06 Phytecs, Inc. Pharmaceutical compositions comprising cannabidiol and beta-caryophyllene and methods for their use
WO2019089558A1 (en) * 2017-10-30 2019-05-09 Endocanna Health, Inc. Graphical user interfaces for determining personalized endocannabinoid genotypes and associated recommendations

Also Published As

Publication number Publication date
EP3817735A1 (en) 2021-05-12
SG11202013235YA (en) 2021-01-28
BR112020027060A2 (pt) 2021-03-30
WO2020006597A1 (en) 2020-01-09
MX2021000024A (es) 2021-05-27
KR20210071940A (ko) 2021-06-16
CA3104739A1 (en) 2020-01-09
AU2018100925A4 (en) 2018-08-09
CL2020003374A1 (es) 2021-08-13
IL279799A (en) 2021-03-01
EP3817735A4 (en) 2022-03-23
AU2019297196A1 (en) 2021-01-28
US20210308092A1 (en) 2021-10-07
CO2021001059A2 (es) 2021-06-30

Similar Documents

Publication Publication Date Title
CO2021001061A2 (es) Composición y método para tratar el dolor
CO2021001059A2 (es) Composición de cannabinoides y método para tratar el ptsd y/o la ansiedad
PE20200676A1 (es) Composicion de cannabis
CO2019014279A2 (es) Proceso para la purificación y separación de cannabinoides a partir de cáñamo seco y hojas de cannabis
PE20230607A1 (es) Composicion de cannabis
PE20200726A1 (es) Composicion de cannabis
CO2017004974A2 (es) Extractos de cannabis y métodos de preparación.
PE20201163A1 (es) Composiciones y tratamientos para el trastorno del sueno
CO2017008437A2 (es) Métodos de purificación de cannabinoides, composiciones y kits de los mismos
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
CY1123351T1 (el) Χρηση του κανναβιδιολικου οξεος στη θεραπεια της επιληψιας
CL2020003373A1 (es) Composición y método de ahorro de opiáceos
CO2019002123A2 (es) Plantas y métodos para aumentar y disminuir la síntesis de cannabinoides
CL2017001893A1 (es) Uso de prg4 como agente antiinflamatorio
MX2020009335A (es) Aislamiento continuo de cannabidiol y conversion de cannabidiol a delta 8-tetrahidro cannabinol y delta 9- tetrahidro cannabinol.
BR112017025424A2 (pt) Composições cosméticas compreendendo e/z-2- benzilindeno-5,6-dimetóxi-3,3-dimetilindan-1-ona
PE20200338A1 (es) Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil
MX2021005476A (es) Plantas de cannabis con un perfil de cannabinoides enriquecidas con ¿-9-tetrahidrocannabinol y cannabigerol.
CL2019000198A1 (es) Nuevas formulaciones y composiciones de cannabis en comprimidos y métodos para su elaboración.
CO2018001840A2 (es) Composiciones biofarmacéuticas que comprenden anticuerpos anti-il-5
MX2020004232A (es) Composiciones de cannabinoides y sus metodos de uso.
BR112016017612A2 (pt) Uso de um extrato de uma planta do gênero mentha da família lamiaceae
CO2018014229A2 (es) Composición biopesticida para uso en prevención o minimizacion de la enfermedad de la planta
EA201991659A1 (ru) Композиция от кашля
AR097111A1 (es) Combinación y método para la administración a un animal